Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of people living with neurological disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, with a focus on advancing multiple Phase 3 trials in epilepsy.